GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Alan Sandler, Oregon Health and Science University, describes how he sees very specialized molecular testing for lung cancer becoming increasingly available to oncologists seeing patients in the community setting.


Dr. Phil Bonomi provides his views on the value of maintenance therapy for advanced non-small cell lung cancer and the various alternatives among maintenance therapies compared with a break from treatment.

Direct download: GRACEcastUC-032_Lung-Video_Bonomi_on_Maintenance_Therapy.m4v
Category:Lung-Cancer-Video -- posted at: 5:08pm PST

Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.


Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA reviews a recommended approach to the workup of a kidney mass suspected to be a cancer.

Direct download: GRACEcastUC-030_Kidney-Video_Pal_on_Kidney_Mass_Evaluation.m4v
Category:Kidney-Cancer-Video -- posted at: 5:46pm PST

Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.

Direct download: GRACEcastUC-029_Lung-Video_Camidge_Langer_on_Who_to_Rebiopsy.m4v
Category:Lung-Cancer-Video -- posted at: 3:23pm PST

Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.


Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for testing in patients with advanced NSCLC, as well as whether smoking status factors into her approach.


Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.


Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.


Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.


Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.

Direct download: GRACEcastUC-023_Lung-Video_Molecular_Marker_Testing_in_NSCLC.m4v
Category:Lung-Cancer-Video -- posted at: 2:28pm PST

Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.

Direct download: GRACEcastUC-022_Lung-Video_What_is_Inherited_T790M_EGFR.m4v
Category:Lung-Cancer-Video -- posted at: 3:03am PST

Dr. William Pao describes the MyCancerGenome.org website and how data on a wide range of mutations is incorporated to build this database to help physicians and cancer patients identify the most promising targeted therapy options for them.

Direct download: GRACEcastUC-021_Lung-Video_What_is_MyCancerGenome.m4v
Category:Lung-Cancer-Video -- posted at: 5:55pm PST

Dr. Jack West describes recent information on the probability that someone with a rare EGFR mutation on exon 20, rather than a more common "activating" mutations on exon 19 or 21, will benefit from an oral EGFR inhibitor vs. standard chemotherapy.

Direct download: GRACEcastUC-020_Lung-Video_How_Approach_Rare_EGFR_Mutation.m4v
Category:Lung-Cancer-Video -- posted at: 8:00am PST

Dr. Jack West describes the factors that contribute to a recommendation for or against post-operative (adjuvant) chemotherapy for a patient with resected early stage non-small cell lung cancer.

Direct download: GRACEcastUC-019_Lung-Video_CiP_Chemo_for_High_Risk_Features.m4v
Category:Lung-Cancer-Video -- posted at: 8:09pm PST

Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.

Direct download: GRACEcast-138_Lung-Video_Advances_in_Lung_Cancer_Staging.m4v
Category:Lung-Cancer-Video -- posted at: 2:52pm PST

Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.

Direct download: GRACEcast-138_Lung-Audio_Advances_in_Lung_Cancer_Staging.mp3
Category:Lung-Cancer-Audio -- posted at: 2:51pm PST

Dr. Jack West describes a case series that illustrates the safety of giving whole brain radiation along with concurrent Tarceva (erlotinib) for patients with lung cancer and brain metastases.

Direct download: GRACEcastUC-018_Radiation-Video_Combine_Tarceva_with_Radiation.m4v
Category:Radiation-Video -- posted at: 9:39pm PST

Dr. Ramalingam answers questions on the changing landscape of cancer clinical trials and how new studies are being designed in the new era of molecular oncology.


Dr. Ramalingam answers questions on the changing landscape of cancer clinical trials and how new studies are being designed in the new era of molecular oncology.